^
    16h
    Discovery of novel FGFR4 inhibitors through a build-up fragment strategy. (PubMed, J Enzyme Inhib Med Chem)
    This strategy resulted in the discovery of a potent inhibitor, 4c, with an IC50 of 33 nM and high selectivity among members of the FGFR family. Although further optimisation is required, our approach demonstrated the potential for discovering potent FGFR4 inhibitors for HCC treatment, and provides a useful method for obtaining hit compounds from small fragments.
    Journal
    |
    FGFR4 (Fibroblast growth factor receptor 4)
    1d
    RAGNAR: A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (clinicaltrials.gov)
    P2, N=316, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2022 --> Dec 2023
    Trial primary completion date • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGFR fusion
    |
    Balversa (erdafitinib)
    1d
    Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. (PubMed, Eur J Surg Oncol)
    Currently, 3 targeted therapies are approved for use in CCA; Ivosidenib in patients with IDH1 mutations and Infigratinib/Pemigatinib in those with FGFR2 fusions. This is important, as it is thought up to 40 % of CCA patients harbour a potentially actionable mutation. In this review we provide an overview of the molecular pathogenesis of CCA and highlight currently available and potential future targeted treatments.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion
    |
    Truseltiq (infigratinib) • Pemazyre (pemigatinib) • Tibsovo (ivosidenib)
    4d
    Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors. (PubMed, Eur J Med Chem)
    It could also regulate FGFR-mediated signaling pathway and mitochondrial apoptotic pathway to promote cancer cell apoptosis and inhibit cancer cell invasion and metastasis. Moreover, III-30 had a good metabolic stability and showed relatively potent anti-tumor activity in the MDA-MB-231 xenograft tumor mice model.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
    4d
    HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study. (PubMed, BMC Cancer)
    Lenvatinib, HAIC and PD-1 showed safe and promising anti-tumor activity compared with lenvatinib alone for HCC with high-risk features.
    Journal • Real-world evidence • Real-world • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    Lenvima (lenvatinib)
    6d
    Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer (clinicaltrials.gov)
    P1/2, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2024 | Trial primary completion date: Dec 2025 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date • Surgery
    |
    Truseltiq (infigratinib)
    6d
    The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. (clinicaltrials.gov)
    P2, N=10, Terminated, Incyte Corporation | Active, not recruiting --> Terminated; A business decision due to availability of commercial drug and other options for accessing study drug treatment.
    Trial termination • Metastases
    |
    Keytruda (pembrolizumab) • Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr)
    7d
    Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Saint Petersburg State University, Russia
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    8d
    Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study. (PubMed, Int J Mol Sci)
    Only one-third of patients with advanced MSS/pMMR endometrial cancer exhibit a lasting response to the combination treatment of Pembrolizumab and Lenvatinib. The sensitivity and specificity of these biomarkers were 85.71% and 70.59%, and 85.71% and 85.71%, respectively. The proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as both a prognostic marker of response to immunotargeted therapy and a prognostic factor for progression-free survival in patients.
    Observational data • Journal • PD(L)-1 Biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    8d
    Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. (PubMed, J Clin Endocrinol Metab)
    Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
    Journal • Metastases
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • RET fusion • ALK fusion • RAS mutation • NTRK fusion
    |
    Lenvima (lenvatinib)
    8d
    A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)-China Extension Study (clinicaltrials.gov)
    P3, N=112, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jul 2026 --> Mar 2025 | Trial primary completion date: Jul 2026 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    8d
    Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. (PubMed, JNCI Cancer Spectr)
    Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC.
    Journal • Metastases
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    Tecentriq (atezolizumab) • derazantinib (ARQ 087)
    9d
    Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Yousef Zakharia | Trial completion date: Sep 2024 --> Jun 2028
    Trial completion date • Metastases
    |
    everolimus • Lenvima (lenvatinib)
    9d
    Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1. (PubMed, JCO Precis Oncol)
    Erdafitinib did not meet its primary end point of efficacy as determined by ORR in treatment-refractory solid tumors harboring FGFR1-4 amplifications. Our findings support that rearrangements and gene mutations, but not amplifications, of FGFR remain the established FGFR alterations with approved indications for FGFR inhibition.
    P2 data • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR1 amplification • FGFR mutation • FGFR amplification
    |
    Balversa (erdafitinib)
    9d
    Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2. (PubMed, JCO Precis Oncol)
    This study met its primary end point in patients with several pretreated solid tumor types harboring FGFR1-3 mutations or fusions. These findings support advancement of erdafitinib for patients with fibroblast growth factor receptor-altered tumors outside of currently approved indications in a potentially tumor-agnostic manner.
    P2 data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGFR1 mutation • FGFR1 fusion
    |
    Balversa (erdafitinib)
    12d
    Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression. (PubMed, Eur Urol)
    No abstract available
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 mutation
    13d
    Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. (PubMed, Expert Opin Pharmacother)
    On the contrary, some patients with mucosal, acral or KIT-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • FLT1 (Fms-related tyrosine kinase 1)
    |
    KIT mutation
    |
    Lenvima (lenvatinib) • AiTan (rivoceranib) • Inlyta (axitinib)
    13d
    Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=300, Recruiting, Peking Union Medical College Hospital
    New P2 trial • Metastases
    |
    cisplatin • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    13d
    SCALE: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Hui-Chuan Sun
    New P2 trial
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    13d
    TAS-120-203: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Taiho Oncology, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
    Enrollment closed • Trial primary completion date • Metastases
    |
    FGFR3 mutation • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    13d
    Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles. (PubMed, J Med Chem)
    Key compounds showed low to subnanomolar potency, efficient covalent inactivation kinetics, and excellent selectivity against the other FGFRs, the kinases with an equivalent cysteine, and a representative subset of the kinome. Moreover, these compounds achieved nanomolar potencies in cellular assays and demonstrated good microsomal stability, highlighting the potential of SNAr-based approaches in covalent inhibitor design.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
    14d
    A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors. (PubMed, Cancer Res Commun)
    The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable PK parameters, though further dose escalation was required to nominate the MTD/RP2D.
    P1 data • Journal • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR mutation
    |
    KIN-3248
    14d
    Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors. (PubMed, Transl Lung Cancer Res)
    No abstract available
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 amplification
    14d
    Futibatinib in Patients With Specific FGFR Aberrations (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 amplification • FGFR1 rearrangement
    |
    Lytgobi (futibatinib)
    16d
    AMBER: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC (clinicaltrials.gov)
    P2, N=0, Withdrawn, ETOP IBCSG Partners Foundation | N=47 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lenvima (lenvatinib) • Lumakras (sotorasib)
    16d
    Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2024 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DEK (DEK Proto-Oncogene) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
    |
    cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    16d
    LENVABLA: Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Recruiting --> Active, not recruiting | N=50 --> 32 | Trial completion date: Feb 2025 --> Oct 2026 | Trial primary completion date: Apr 2024 --> Jul 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
    |
    Lenvima (lenvatinib)
    17d
    Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    Balversa (erdafitinib)
    19d
    Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. (PubMed, Eur Urol)
    No abstract available
    P3 data • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    Truseltiq (infigratinib)
    21d
    FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=47, Terminated, Basilea Pharmaceutica | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    HER-2 negative • FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR1 fusion • FGFR3 fusion
    |
    Tecentriq (atezolizumab) • paclitaxel • Cyramza (ramucirumab) • derazantinib (ARQ 087)
    21d
    Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma. (PubMed, J Urol)
    We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations...Renal preservation was enabled in a substantial proportion of participants. These data support the design of a biomarker-driven phase 2 trial of FGFR3 inhibition in this population with significant unmet clinical needs.
    P1 data • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    Truseltiq (infigratinib)
    21d
    A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality. (PubMed, Acta Pharm)
    FDA has approved four anticancer agents such as erdafitinib, pemigatinib, infigratinib, and futibatinib, for clinical use in oncogenic FGFR-driven malignancies. Furthermore, futibatinib is the first-in-class covalent or irreversible pan-FGFR inhibitor that has received FDA approval for locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene aberrations. This review highlights the current clinical progress concerning the safety and efficacy of all the approved FGFR-TKIs (tyrosine kinase inhibitors) and their ongoing investigations in clinical trials for other oncogenic FGFR-driven malignancies.
    Review • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 fusion • FGFR1 fusion • FGFR1 rearrangement
    |
    Balversa (erdafitinib) • Truseltiq (infigratinib) • Lytgobi (futibatinib) • Pemazyre (pemigatinib)
    22d
    Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells. (PubMed, Breast Cancer Res)
    Overall, our findings reveal a divergence in FGFR signaling, transitioning from a proliferative to stemness state driven by activation of JAK-STAT signaling and modulation of p21 levels. Activation of these divergent signaling pathways in FGFR amplified cancer cells and paradoxical growth effects highlight a challenge in the use of FGFR inhibitors in cancer treatment.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGF2 (Fibroblast Growth Factor 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    FGFR1 amplification • FGFR1 expression • FGFR amplification
    24d
    Nuclear KRT19 is a transcriptional co-repressor promoting histone deacetylation and liver tumorigenesis. (PubMed, Hepatology)
    Our data show that nuclear KRT19 acts as a transcriptional co-repressor through promoting the deacetylase activity of the CoREST complex, resulting in dedifferentiation of liver cancer. These findings reveal a previously unrecognized function of KRT19 in directly shaping the epigenetic landscape in cancer.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • KRT19 (Keratin 19) • HNF1A (HNF1 Homeobox A)
    |
    Lenvima (lenvatinib)
    24d
    Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma. (PubMed, Anticancer Res)
    Surgical intervention after lenvatinib treatment for advanced HCC was associated with longer PFS. Patients exhibiting decreased AFP levels or maintaining AFP levels within the normal limit may be suitable candidates for surgical intervention after lenvatinib treatment for advanced HCC.
    Journal • Metastases
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    Lenvima (lenvatinib)
    24d
    Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Peking Union Medical College Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    27d
    A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=35, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Metastases
    |
    FGFR mutation
    |
    Balversa (erdafitinib)
    27d
    Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial primary completion date: Sep 2024 --> May 2025
    Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    FGF19 (Fibroblast growth factor 19)
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    28d
    Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib. (PubMed, Discov Oncol)
    Pulrodemstat synergized with Lenvatinib based on suppression of PI3K-AKT signaling and activation of apoptotic signaling.
    Journal
    |
    CASP3 (Caspase 3)
    |
    Lenvima (lenvatinib) • pulrodemstat (CC-90011)
    29d
    HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Sun Yat-sen University
    New trial • Real-world evidence • Real-world
    |
    5-fluorouracil • Tyvyt (sintilimab) • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab) • oxaliplatin
    29d
    THOR: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (clinicaltrials.gov)
    P3, N=629, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2024 --> Sep 2024
    Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • docetaxel • Balversa (erdafitinib) • Javlor (vinflunine)
    29d
    Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer (clinicaltrials.gov)
    P1, N=112, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Apr 2025 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGFR fusion
    |
    erdafitinib intravesical delivery system (TAR-210)